The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Lixte Biotechnology Holdings's share price is $2.525.
Lixte Biotechnology Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00. Hence, Lixte Biotechnology Holdings's PS Ratio for today is .
The historical rank and industry rank for Lixte Biotechnology Holdings's PS Ratio or its related term are showing as below:
During the past 13 years, Lixte Biotechnology Holdings's highest PS Ratio was 322.71. The lowest was 7.41. And the median was 50.22.
LIXT's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.29 * Ranked among companies with meaningful PS Ratio only.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lixte Biotechnology Holdings's PS Ratio
For the Biotechnology subindustry, Lixte Biotechnology Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lixte Biotechnology Holdings's PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lixte Biotechnology Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Lixte Biotechnology Holdings's PS Ratio falls into.
Lixte Biotechnology Holdings PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Lixte Biotechnology Holdings's Share Price of today is $2.525. Lixte Biotechnology Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Lixte Biotechnology Holdings (NAS:LIXT) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Lixte Biotechnology Holdings PS Ratio Related Terms
Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) Business Description
Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LIXT has been successfully added to your 